[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMnUszXQYL2WWyxlw0Dqa48FORg9avYENYGTFUaHIITw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Prince of Songkla University",[4],114,false,9,16,15050,2,73,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Intraocular Pressure",4,{"name":18,"count":19},"Healthy",3,{"name":21,"count":19},"Postoperative Pain",{"name":23,"count":19},"Pain",{"name":25,"count":11},"Inadequate or Impaired Breathing Pattern or Ventilation",{"name":27,"count":11},"High-Frequency Ventilation",{"name":29,"count":11},"Newborn Morbidity",{"name":31,"count":11},"Agitation",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06265870","Specific Versus Empirical Anthelminthic Treatment in Eosinophilia","2025-12-31","Albendazole",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,71,89,117,135,153,179,197,224,251,269,293,317,342,368,393,420,447,474,499,525,543,568,593,618,645,663,681,705,731,757,781,806,832,858,876,934,962,992,1020,1038,1056,1084,1102,1128,1153,1171,1197,1224,1242,1266,1291],{"intervention":37,"totalTrials":47,"cells":48},1,{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":60},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":51},[],{"trials":61,"activeCount":47,"soonestReadout":36},[62],{"nctId":34,"briefTitle":35,"status":63,"phases":64,"primaryCompletion":36,"completion":36,"start":65,"enrollment":66,"conditions":67,"interventions":69},"RECRUITING",[44],"2024-05-01",700,[68],"Eosinophilia",[37,70],"Ivermectin or albendazole",{"intervention":70,"totalTrials":47,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":83},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[],{"trials":84,"activeCount":47,"soonestReadout":36},[85],{"nctId":34,"briefTitle":35,"status":63,"phases":86,"primaryCompletion":36,"completion":36,"start":65,"enrollment":66,"conditions":87,"interventions":88},[44],[68],[37,70],{"intervention":90,"totalTrials":47,"cells":91},"Propofol",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":115},{"trials":93,"activeCount":51},[],{"trials":95,"activeCount":51},[],{"trials":97,"activeCount":51},[],{"trials":99,"activeCount":51},[],{"trials":101,"activeCount":51},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT01709422","Efficacy and Safety Profiles of Combination Sedation Propofol With Midazolam and Meperidine.","COMPLETED",[43],"2012-11","2010-06",140,[111],"Disorders of Gallbladder, Biliary Tract and Pancrease",[90,113,114],"Midazolam","Meperidine",{"trials":116,"activeCount":51},[],{"intervention":113,"totalTrials":47,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":133},{"trials":120,"activeCount":51},[],{"trials":122,"activeCount":51},[],{"trials":124,"activeCount":51},[],{"trials":126,"activeCount":51},[],{"trials":128,"activeCount":51},[129],{"nctId":103,"briefTitle":104,"status":105,"phases":130,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":131,"interventions":132},[43],[111],[90,113,114],{"trials":134,"activeCount":51},[],{"intervention":114,"totalTrials":47,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":151},{"trials":138,"activeCount":51},[],{"trials":140,"activeCount":51},[],{"trials":142,"activeCount":51},[],{"trials":144,"activeCount":51},[],{"trials":146,"activeCount":51},[147],{"nctId":103,"briefTitle":104,"status":105,"phases":148,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":149,"interventions":150},[43],[111],[90,113,114],{"trials":152,"activeCount":51},[],{"intervention":154,"totalTrials":47,"cells":155},"Parecoxib",{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":177},{"trials":157,"activeCount":51},[],{"trials":159,"activeCount":51},[],{"trials":161,"activeCount":51},[],{"trials":163,"activeCount":51},[],{"trials":165,"activeCount":51},[166],{"nctId":167,"briefTitle":168,"status":105,"phases":169,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":175},"NCT01859585","Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion",[43],"2013-01","2013-03","2011-03",96,[21],[154,176],"Ketorolac",{"trials":178,"activeCount":51},[],{"intervention":176,"totalTrials":47,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":195},{"trials":182,"activeCount":51},[],{"trials":184,"activeCount":51},[],{"trials":186,"activeCount":51},[],{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[191],{"nctId":167,"briefTitle":168,"status":105,"phases":192,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":193,"interventions":194},[43],[21],[154,176],{"trials":196,"activeCount":51},[],{"intervention":198,"totalTrials":47,"cells":199},"Ertapenem",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":222},{"trials":201,"activeCount":51},[],{"trials":203,"activeCount":51},[],{"trials":205,"activeCount":51},[],{"trials":207,"activeCount":51},[],{"trials":209,"activeCount":51},[210],{"nctId":211,"briefTitle":212,"status":213,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":221},"NCT03859362","Ertapenem in Patients With Urosepsis","UNKNOWN",[43],"2018-12-30","2021-12-31","2017-01",12,[220],"Patients With Urosepis and Received Ertapenem for Treatment",[198],{"trials":223,"activeCount":51},[],{"intervention":225,"totalTrials":47,"cells":226},"intramuscular depot medroxyprogesterone acetate",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":249},{"trials":228,"activeCount":51},[],{"trials":230,"activeCount":51},[],{"trials":232,"activeCount":51},[],{"trials":234,"activeCount":51},[],{"trials":236,"activeCount":51},[237],{"nctId":238,"briefTitle":239,"status":105,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT01056042","Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain",[43],"2011-04","2011-10","2007-06",112,[246],"Endometriosis",[225,248],"ethinyl estradiol 30 micrograms, gestodene 75 micrograms",{"trials":250,"activeCount":51},[],{"intervention":248,"totalTrials":47,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":267},{"trials":254,"activeCount":51},[],{"trials":256,"activeCount":51},[],{"trials":258,"activeCount":51},[],{"trials":260,"activeCount":51},[],{"trials":262,"activeCount":51},[263],{"nctId":238,"briefTitle":239,"status":105,"phases":264,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":265,"interventions":266},[43],[246],[225,248],{"trials":268,"activeCount":51},[],{"intervention":270,"totalTrials":47,"cells":271},"Travoprost",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":291},{"trials":273,"activeCount":51},[],{"trials":275,"activeCount":51},[],{"trials":277,"activeCount":51},[],{"trials":279,"activeCount":51},[],{"trials":281,"activeCount":51},[282],{"nctId":283,"briefTitle":284,"status":105,"phases":285,"primaryCompletion":286,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":290},"NCT02105311","Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure",[43],"2016-02","2014-03",60,[15],[270],{"trials":292,"activeCount":51},[],{"intervention":294,"totalTrials":47,"cells":295},"Pregabalin",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":304,"NA":315},{"trials":297,"activeCount":51},[],{"trials":299,"activeCount":51},[],{"trials":301,"activeCount":51},[],{"trials":303,"activeCount":51},[],{"trials":305,"activeCount":51},[306],{"nctId":307,"briefTitle":308,"status":105,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":288,"conditions":312,"interventions":314},"NCT01242332","Perioperative Administration of Pregabalin in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction",[43],"2010-10","2009-08",[313],"Postoperative Pain Management",[294],{"trials":316,"activeCount":51},[],{"intervention":318,"totalTrials":47,"cells":319},"LGG",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":328,"NA":340},{"trials":321,"activeCount":51},[],{"trials":323,"activeCount":51},[],{"trials":325,"activeCount":51},[],{"trials":327,"activeCount":51},[],{"trials":329,"activeCount":51},[330],{"nctId":331,"briefTitle":332,"status":213,"phases":333,"primaryCompletion":36,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT06310733","The Effects of Probiotics, Lactobacillus GG, in the Treatment of Abdominal Pain in Children With Functional Abdominal Pain Disorders",[43],"2026-02-20","2024-03-21",54,[338],"Functional Abdominal Pain Syndrome",[318],{"trials":341,"activeCount":51},[],{"intervention":343,"totalTrials":47,"cells":344},"Baby talcum",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":364,"NA":366},{"trials":346,"activeCount":51},[],{"trials":348,"activeCount":51},[],{"trials":350,"activeCount":51},[],{"trials":352,"activeCount":51},[353],{"nctId":354,"briefTitle":355,"status":213,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":363},"NCT01017315","Efficacy of Baby Talcum in Prevention of Pruritus Assosiated With Cast",[42],"2012-07","2012-10","2009-07",50,[362],"Fracture Distal Radius",[343],{"trials":365,"activeCount":51},[],{"trials":367,"activeCount":51},[],{"intervention":369,"totalTrials":47,"cells":370},"Ivermectin",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":389,"NA":391},{"trials":372,"activeCount":51},[],{"trials":374,"activeCount":51},[],{"trials":376,"activeCount":51},[],{"trials":378,"activeCount":51},[379],{"nctId":380,"briefTitle":381,"status":105,"phases":382,"primaryCompletion":216,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},"NCT06259383","Oral Ivermectin for Chikungunya Viral Infection",[42],"2024-01-26","2018-01-01",120,[387],"Clinical Syndrome",[369],{"trials":390,"activeCount":51},[],{"trials":392,"activeCount":51},[],{"intervention":394,"totalTrials":47,"cells":395},"etoricoxib",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":416,"NA":418},{"trials":397,"activeCount":51},[],{"trials":399,"activeCount":51},[],{"trials":401,"activeCount":51},[],{"trials":403,"activeCount":51},[404],{"nctId":405,"briefTitle":406,"status":105,"phases":407,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":414},"NCT01017380","Preemptive Analgesia in Cruciate Reconstruction",[42],"2009-01","2009-06","2008-01",30,[413],"Anterior Cruciate Ligament Injury",[415,394],"Celecoxib",{"trials":417,"activeCount":51},[],{"trials":419,"activeCount":51},[],{"intervention":421,"totalTrials":47,"cells":422},"Roflumilast",{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":443,"NA":445},{"trials":424,"activeCount":51},[],{"trials":426,"activeCount":51},[],{"trials":428,"activeCount":51},[],{"trials":430,"activeCount":51},[431],{"nctId":432,"briefTitle":433,"status":105,"phases":434,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":442},"NCT04122547","Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis",[42],"2015-12","2015-01",40,[439,440,441],"Exacerbation Copd","Bronchiectasis","Lung Function Decreased",[421],{"trials":444,"activeCount":51},[],{"trials":446,"activeCount":51},[],{"intervention":448,"totalTrials":47,"cells":449},"Prucalopride",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":470,"NA":472},{"trials":451,"activeCount":51},[],{"trials":453,"activeCount":51},[],{"trials":455,"activeCount":51},[],{"trials":457,"activeCount":51},[458],{"nctId":459,"briefTitle":460,"status":213,"phases":461,"primaryCompletion":462,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":469},"NCT04190173","Efficacy of PRUcalopride in Critically Ill Patients With Paralytic ILeus",[42],"2020-01-30","2020-02-15","2017-07-01",62,[467,468],"Paralytic Ileus","Critically Ill",[448],{"trials":471,"activeCount":51},[],{"trials":473,"activeCount":51},[],{"intervention":475,"totalTrials":47,"cells":476},"Ferrous Fumarate",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":495,"NA":497},{"trials":478,"activeCount":51},[],{"trials":480,"activeCount":51},[],{"trials":482,"activeCount":51},[],{"trials":484,"activeCount":51},[485],{"nctId":486,"briefTitle":487,"status":105,"phases":488,"primaryCompletion":489,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":494},"NCT04130828","Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia",[42],"2022-01-18","2020-01-21",66,[493],"Iron Deficiency Anemia",[475],{"trials":496,"activeCount":51},[],{"trials":498,"activeCount":51},[],{"intervention":500,"totalTrials":47,"cells":501},"Bevacizumab",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":521,"NA":523},{"trials":503,"activeCount":51},[],{"trials":505,"activeCount":51},[],{"trials":507,"activeCount":51},[],{"trials":509,"activeCount":51},[510],{"nctId":511,"briefTitle":512,"status":105,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT01263834","Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome",[41,42],"2014-01","2010-12",39,[518],"Glaucoma",[500,520],"Mitomycin C",{"trials":522,"activeCount":51},[],{"trials":524,"activeCount":51},[],{"intervention":520,"totalTrials":47,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":539,"NA":541},{"trials":528,"activeCount":51},[],{"trials":530,"activeCount":51},[],{"trials":532,"activeCount":51},[],{"trials":534,"activeCount":51},[535],{"nctId":511,"briefTitle":512,"status":105,"phases":536,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":537,"interventions":538},[41,42],[518],[500,520],{"trials":540,"activeCount":51},[],{"trials":542,"activeCount":51},[],{"intervention":544,"totalTrials":47,"cells":545},"Roxithromycin 300 MG",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":564,"NA":566},{"trials":547,"activeCount":51},[],{"trials":549,"activeCount":51},[],{"trials":551,"activeCount":51},[],{"trials":553,"activeCount":51},[554],{"nctId":555,"briefTitle":556,"status":105,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":437,"conditions":560,"interventions":563},"NCT04122040","Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis",[42],"2011-09-30","2011-03-01",[561,562],"Quality of Life","Respiratory Function Tests",[544],{"trials":565,"activeCount":51},[],{"trials":567,"activeCount":51},[],{"intervention":569,"totalTrials":47,"cells":570},"silversulfadiazine",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":589,"NA":591},{"trials":572,"activeCount":51},[],{"trials":574,"activeCount":51},[],{"trials":576,"activeCount":51},[],{"trials":578,"activeCount":51},[579],{"nctId":580,"briefTitle":581,"status":105,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":411,"conditions":586,"interventions":588},"NCT01017094","Pin Site Infection Prevention for Open Tibial Fracture",[42],"2008-06","2009-11","2007-09",[587],"Tibial Fracture",[569],{"trials":590,"activeCount":51},[],{"trials":592,"activeCount":51},[],{"intervention":594,"totalTrials":47,"cells":595},"benzydamine HCl",{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":614,"NA":616},{"trials":597,"activeCount":51},[],{"trials":599,"activeCount":51},[],{"trials":601,"activeCount":51},[],{"trials":603,"activeCount":51},[604],{"nctId":605,"briefTitle":606,"status":213,"phases":607,"primaryCompletion":357,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT01637883","Benzydamine HCl for Postoperative Sore Throat",[42],"2012-08","2011-01",86,[612],"For Intervention",[594],{"trials":615,"activeCount":51},[],{"trials":617,"activeCount":51},[],{"intervention":619,"totalTrials":47,"cells":620},"Dexamethasone",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":622,"activeCount":51},[],{"trials":624,"activeCount":51},[],{"trials":626,"activeCount":51},[627],{"nctId":628,"briefTitle":629,"status":105,"phases":630,"primaryCompletion":631,"start":632,"enrollment":633,"conditions":634,"interventions":636},"NCT01543945","Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy",[41],"2011-12","2008-03",340,[635],"Postoperative Nausea and Vomiting",[619,637,638],"Ondansetron","Dimenhydrinate",{"trials":640,"activeCount":51},[],{"trials":642,"activeCount":51},[],{"trials":644,"activeCount":51},[],{"intervention":637,"totalTrials":47,"cells":646},{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":648,"activeCount":51},[],{"trials":650,"activeCount":51},[],{"trials":652,"activeCount":51},[653],{"nctId":628,"briefTitle":629,"status":105,"phases":654,"primaryCompletion":631,"start":632,"enrollment":633,"conditions":655,"interventions":656},[41],[635],[619,637,638],{"trials":658,"activeCount":51},[],{"trials":660,"activeCount":51},[],{"trials":662,"activeCount":51},[],{"intervention":638,"totalTrials":47,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":666,"activeCount":51},[],{"trials":668,"activeCount":51},[],{"trials":670,"activeCount":51},[671],{"nctId":628,"briefTitle":629,"status":105,"phases":672,"primaryCompletion":631,"start":632,"enrollment":633,"conditions":673,"interventions":674},[41],[635],[619,637,638],{"trials":676,"activeCount":51},[],{"trials":678,"activeCount":51},[],{"trials":680,"activeCount":51},[],{"intervention":682,"totalTrials":47,"cells":683},"antioxidants",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":685,"activeCount":51},[],{"trials":687,"activeCount":51},[],{"trials":689,"activeCount":51},[690],{"nctId":691,"briefTitle":692,"status":105,"phases":693,"primaryCompletion":694,"completion":409,"start":695,"enrollment":288,"conditions":696,"interventions":698},"NCT00963131","High-dose Antioxidants for Central Serous Chorioretinopathy",[41],"2008-12","2004-12",[697],"Central Serous Chorioretinopathy",[682],{"trials":700,"activeCount":51},[],{"trials":702,"activeCount":51},[],{"trials":704,"activeCount":51},[],{"intervention":706,"totalTrials":47,"cells":707},"BKM120",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":709,"activeCount":51},[],{"trials":711,"activeCount":51},[],{"trials":713,"activeCount":51},[714],{"nctId":715,"briefTitle":716,"status":717,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT01806649","BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy","TERMINATED",[41],"2016-04-30","2013-07-01",5,[723],"Esophageal Cancer",[706],{"trials":726,"activeCount":51},[],{"trials":728,"activeCount":51},[],{"trials":730,"activeCount":51},[],{"intervention":732,"totalTrials":47,"cells":733},"Levofloxacin",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":735,"activeCount":51},[],{"trials":737,"activeCount":51},[],{"trials":739,"activeCount":51},[740],{"nctId":741,"briefTitle":742,"status":105,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT02699658","Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin",[41],"2014-08","2014-09","2013-10",45,[749],"Healthy Volunteers",[732],{"trials":752,"activeCount":51},[],{"trials":754,"activeCount":51},[],{"trials":756,"activeCount":51},[],{"intervention":758,"totalTrials":47,"cells":759},"Linezolid oral tablet 300 mg\u002Fday for 5 day",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":761,"activeCount":51},[],{"trials":763,"activeCount":51},[764],{"nctId":765,"briefTitle":766,"status":213,"phases":767,"primaryCompletion":768,"completion":769,"start":770,"enrollment":411,"conditions":771,"interventions":772},"NCT03841721","Linezolid in Healthy Volunteers",[40],"2018-08-01","2019-12-31","2018-05-01",[18],[758],{"trials":774,"activeCount":51},[],{"trials":776,"activeCount":51},[],{"trials":778,"activeCount":51},[],{"trials":780,"activeCount":51},[],{"intervention":782,"totalTrials":47,"cells":783},"SBG",{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":785,"activeCount":51},[],{"trials":787,"activeCount":51},[788],{"nctId":789,"briefTitle":790,"status":105,"phases":791,"primaryCompletion":792,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":797},"NCT01910597","Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors",[40],"2016-04-20","2013-08-01",10,[796],"Advanced Solid Tumors",[782],{"trials":799,"activeCount":51},[],{"trials":801,"activeCount":51},[],{"trials":803,"activeCount":51},[],{"trials":805,"activeCount":51},[],{"intervention":807,"totalTrials":47,"cells":808},"Vaccine",{"EARLY_PHASE1":809,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":810,"activeCount":51},[811],{"nctId":812,"briefTitle":813,"status":105,"phases":814,"primaryCompletion":815,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":821},"NCT06837116","Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers",[39],"2025-08-30","2025-09-30","2025-04-19",29,[820],"Dengue",[807],{"trials":823,"activeCount":51},[],{"trials":825,"activeCount":51},[],{"trials":827,"activeCount":51},[],{"trials":829,"activeCount":51},[],{"trials":831,"activeCount":51},[],{"intervention":833,"totalTrials":47,"cells":834},"Bivalent mRNA SARS-CoV-2 vaccine",{"EARLY_PHASE1":835,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":836,"activeCount":51},[837],{"nctId":838,"briefTitle":839,"status":105,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":843,"conditions":844,"interventions":846},"NCT06831786","Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers",[39],"2024-05-31","2024-03-01",36,[845],"COVID - 19",[833,847],"Quardrivalent influenza vaccine",{"trials":849,"activeCount":51},[],{"trials":851,"activeCount":51},[],{"trials":853,"activeCount":51},[],{"trials":855,"activeCount":51},[],{"trials":857,"activeCount":51},[],{"intervention":847,"totalTrials":47,"cells":859},{"EARLY_PHASE1":860,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":861,"activeCount":51},[862],{"nctId":838,"briefTitle":839,"status":105,"phases":863,"primaryCompletion":841,"completion":841,"start":842,"enrollment":843,"conditions":864,"interventions":865},[39],[845],[833,847],{"trials":867,"activeCount":51},[],{"trials":869,"activeCount":51},[],{"trials":871,"activeCount":51},[],{"trials":873,"activeCount":51},[],{"trials":875,"activeCount":51},[],{"intervention":877,"totalTrials":16,"cells":878},"Imipenem",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":887,"NA":920},{"trials":880,"activeCount":51},[],{"trials":882,"activeCount":51},[],{"trials":884,"activeCount":51},[],{"trials":886,"activeCount":51},[],{"trials":888,"activeCount":51},[889,899,910],{"nctId":890,"briefTitle":891,"status":213,"phases":892,"primaryCompletion":893,"completion":894,"start":895,"enrollment":218,"conditions":896,"interventions":898},"NCT03776305","Imipenem in Critically Ill Patients",[43],"2018-02-01","2020-12-30","2015-12-01",[897],"Critically Ill Patients With ECMO",[877],{"nctId":900,"briefTitle":901,"status":105,"phases":902,"primaryCompletion":903,"completion":904,"start":905,"enrollment":906,"conditions":907,"interventions":909},"NCT01379157","Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia",[43],"2013-08","2014-07","2011-11",8,[908],"Ventilator Associated Pneumonia",[877,877],{"nctId":911,"briefTitle":912,"status":105,"phases":913,"primaryCompletion":914,"completion":915,"start":916,"enrollment":218,"conditions":917,"interventions":919},"NCT02213783","Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia",[43],"2013-07","2013-09","2011-02",[918],"Patients With Febrile Neutropenia",[877,877],{"trials":921,"activeCount":51},[922],{"nctId":923,"briefTitle":924,"status":213,"phases":925,"primaryCompletion":926,"completion":216,"start":927,"enrollment":928,"conditions":929,"interventions":932},"NCT03858387","PK\u002FPD and Clinial Outcomes of Beta-lactams in ICU Patients",[],"2020-12-31","2018-09-01",102,[930,931],"Critical Illness","Bacterial Infections",[933,877],"Meropenem",{"intervention":415,"totalTrials":11,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":948,"NA":950},{"trials":937,"activeCount":51},[],{"trials":939,"activeCount":51},[],{"trials":941,"activeCount":51},[],{"trials":943,"activeCount":51},[944],{"nctId":405,"briefTitle":406,"status":105,"phases":945,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":946,"interventions":947},[42],[413],[415,394],{"trials":949,"activeCount":51},[],{"trials":951,"activeCount":51},[952],{"nctId":953,"briefTitle":954,"status":213,"phases":955,"primaryCompletion":956,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":961},"NCT04997174","Comparison of Postoperative Pain Management in Patients Undergoing Laparoscopic Colorectal Surgery Under Enhanced Recovery After Surgery (ERAS) Program, Laparoscopic Colorectal Surgery Without ERAS and Open Colorectal Surgery",[],"2021-12","2022-12","2021-10",162,[21],[415],{"intervention":963,"totalTrials":11,"cells":964},"meropenem",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":966,"activeCount":51},[],{"trials":968,"activeCount":51},[],{"trials":970,"activeCount":51},[],{"trials":972,"activeCount":51},[],{"trials":974,"activeCount":51},[],{"trials":976,"activeCount":51},[977,988],{"nctId":978,"briefTitle":979,"status":213,"phases":980,"primaryCompletion":981,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT05042271","PK of Meropenem in Patients on Plasma Exchange",[],"2021-10-18","2022-12-31","2020-01-01",15,[986],"Autoimmune Diseases",[963],{"nctId":923,"briefTitle":924,"status":213,"phases":989,"primaryCompletion":926,"completion":216,"start":927,"enrollment":928,"conditions":990,"interventions":991},[],[930,931],[933,877],{"intervention":993,"totalTrials":47,"cells":994},"Chemotherapy drug",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":996,"activeCount":51},[],{"trials":998,"activeCount":51},[],{"trials":1000,"activeCount":51},[],{"trials":1002,"activeCount":51},[],{"trials":1004,"activeCount":51},[],{"trials":1006,"activeCount":51},[1007],{"nctId":1008,"briefTitle":1009,"status":213,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1017},"NCT06326086","Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy\u002FImmunotherapy, Before and After Treatment.",[],"2024-08-01","2022-08-01",240,[1015,1016],"Advanced Lung Cancer","Sarcopenia",[993,1018,1019],"Targeted Agent","Immunotherapy",{"intervention":1018,"totalTrials":47,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1023,"activeCount":51},[],{"trials":1025,"activeCount":51},[],{"trials":1027,"activeCount":51},[],{"trials":1029,"activeCount":51},[],{"trials":1031,"activeCount":51},[],{"trials":1033,"activeCount":51},[1034],{"nctId":1008,"briefTitle":1009,"status":213,"phases":1035,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":1036,"interventions":1037},[],[1015,1016],[993,1018,1019],{"intervention":1019,"totalTrials":47,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1041,"activeCount":51},[],{"trials":1043,"activeCount":51},[],{"trials":1045,"activeCount":51},[],{"trials":1047,"activeCount":51},[],{"trials":1049,"activeCount":51},[],{"trials":1051,"activeCount":51},[1052],{"nctId":1008,"briefTitle":1009,"status":213,"phases":1053,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":1054,"interventions":1055},[],[1015,1016],[993,1018,1019],{"intervention":1057,"totalTrials":47,"cells":1058},"TGC",{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1065,"PHASE4":1067,"NA":1069},{"trials":1060,"activeCount":51},[],{"trials":1062,"activeCount":51},[],{"trials":1064,"activeCount":51},[],{"trials":1066,"activeCount":51},[],{"trials":1068,"activeCount":51},[],{"trials":1070,"activeCount":51},[1071],{"nctId":1072,"briefTitle":1073,"status":717,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1082},"NCT01225159","Tight Glycaemic Control During Cardiac Surgery",[44],"2009-03","2008-09",200,[1079,1080,1081],"Nosocomial Infection","External Causes of Morbidity and Mortality","Hypoglycemia",[1057,1083],"Conventional glycaemic control",{"intervention":1083,"totalTrials":47,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1087,"activeCount":51},[],{"trials":1089,"activeCount":51},[],{"trials":1091,"activeCount":51},[],{"trials":1093,"activeCount":51},[],{"trials":1095,"activeCount":51},[],{"trials":1097,"activeCount":51},[1098],{"nctId":1072,"briefTitle":1073,"status":717,"phases":1099,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1100,"interventions":1101},[44],[1079,1080,1081],[1057,1083],{"intervention":1103,"totalTrials":47,"cells":1104},"Propofol Fresenius",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":51},[],{"trials":1108,"activeCount":51},[],{"trials":1110,"activeCount":51},[],{"trials":1112,"activeCount":51},[],{"trials":1114,"activeCount":51},[],{"trials":1116,"activeCount":51},[1117],{"nctId":1118,"briefTitle":1119,"status":105,"phases":1120,"primaryCompletion":1121,"completion":1122,"start":1123,"enrollment":437,"conditions":1124,"interventions":1127},"NCT04664595","Requirements of Propofol With Target Controlled Infusions for Supraglottic Airway Devices",[44],"2013-06","2013-12","2012-06",[1125,1126],"Appropriate Affect","Complication of Device Insertion",[1103],{"intervention":1129,"totalTrials":47,"cells":1130},"fentanyl",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1132,"activeCount":51},[],{"trials":1134,"activeCount":51},[],{"trials":1136,"activeCount":51},[],{"trials":1138,"activeCount":51},[],{"trials":1140,"activeCount":51},[],{"trials":1142,"activeCount":51},[1143],{"nctId":1144,"briefTitle":1145,"status":105,"phases":1146,"primaryCompletion":1147,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1151},"NCT01440114","The Effect of Intravenous Fentanyl Prior the End of Surgery on Emergence Agitation in Paediatric Patients After General Anesthesia",[44],"2011-07","2010-03",144,[31],[1129,1152],"NSS",{"intervention":1152,"totalTrials":47,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1161,"PHASE4":1163,"NA":1165},{"trials":1156,"activeCount":51},[],{"trials":1158,"activeCount":51},[],{"trials":1160,"activeCount":51},[],{"trials":1162,"activeCount":51},[],{"trials":1164,"activeCount":51},[],{"trials":1166,"activeCount":51},[1167],{"nctId":1144,"briefTitle":1145,"status":105,"phases":1168,"primaryCompletion":1147,"completion":1147,"start":1148,"enrollment":1149,"conditions":1169,"interventions":1170},[44],[31],[1129,1152],{"intervention":1172,"totalTrials":47,"cells":1173},"Gabapentin",{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1175,"activeCount":51},[],{"trials":1177,"activeCount":51},[],{"trials":1179,"activeCount":51},[],{"trials":1181,"activeCount":51},[],{"trials":1183,"activeCount":51},[],{"trials":1185,"activeCount":51},[1186],{"nctId":1187,"briefTitle":1188,"status":105,"phases":1189,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1196},"NCT01236859","Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus",[44],"2010-08","2010-11","2009-09",180,[1195],"Pruritus",[1172],{"intervention":1198,"totalTrials":47,"cells":1199},"Desflurane",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1206,"PHASE4":1208,"NA":1210},{"trials":1201,"activeCount":51},[],{"trials":1203,"activeCount":51},[],{"trials":1205,"activeCount":51},[],{"trials":1207,"activeCount":51},[],{"trials":1209,"activeCount":51},[],{"trials":1211,"activeCount":51},[1212],{"nctId":1213,"briefTitle":1214,"status":105,"phases":1215,"primaryCompletion":608,"completion":608,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1222},"NCT01235143","Emergence Agitation Between Sevoflurane and Desflurane in Pediatric",[44],"2010-05",136,[1219,1220,1221],"Children","Urologic Diseases","Ambulation Difficulty",[1198,1223],"Sevoflurane",{"intervention":1223,"totalTrials":47,"cells":1225},{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1227,"activeCount":51},[],{"trials":1229,"activeCount":51},[],{"trials":1231,"activeCount":51},[],{"trials":1233,"activeCount":51},[],{"trials":1235,"activeCount":51},[],{"trials":1237,"activeCount":51},[1238],{"nctId":1213,"briefTitle":1214,"status":105,"phases":1239,"primaryCompletion":608,"completion":608,"start":1216,"enrollment":1217,"conditions":1240,"interventions":1241},[44],[1219,1220,1221],[1198,1223],{"intervention":1243,"totalTrials":47,"cells":1244},"Lidocaine",{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1246,"activeCount":51},[],{"trials":1248,"activeCount":51},[],{"trials":1250,"activeCount":51},[],{"trials":1252,"activeCount":51},[],{"trials":1254,"activeCount":51},[],{"trials":1256,"activeCount":51},[1257],{"nctId":1258,"briefTitle":1259,"status":105,"phases":1260,"primaryCompletion":584,"completion":584,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1265},"NCT01345981","A Comparison of Pain Severity on Injection of MCT\u002FLCT Propofol Between Lidocaine 20 mg, 40 mg, and Without Lidocaine.",[44],"2008-10",210,[1264],"Adult Disease",[1243],{"intervention":1267,"totalTrials":47,"cells":1268},"ranibizumab",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1270,"activeCount":51},[],{"trials":1272,"activeCount":51},[],{"trials":1274,"activeCount":51},[],{"trials":1276,"activeCount":51},[],{"trials":1278,"activeCount":51},[],{"trials":1280,"activeCount":51},[1281],{"nctId":1282,"briefTitle":1283,"status":105,"phases":1284,"primaryCompletion":694,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1290},"NCT00539734","Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration",[44],"2009-02","2007-08",25,[1289],"Age-related Macular Degeneration",[1267],{"intervention":1292,"totalTrials":47,"cells":1293},"Intravitreal",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1304},{"trials":1295,"activeCount":51},[],{"trials":1297,"activeCount":51},[],{"trials":1299,"activeCount":51},[],{"trials":1301,"activeCount":51},[],{"trials":1303,"activeCount":51},[],{"trials":1305,"activeCount":51},[1306],{"nctId":1307,"briefTitle":1308,"status":105,"phases":1309,"primaryCompletion":1310,"completion":1310,"start":1122,"enrollment":1311,"conditions":1312,"interventions":1313},"NCT02474225","Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent",[],"2015-05",70,[15],[1292]]